- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06228768
Acupressure for Aromatase Inhibitor-Associated Musculoskeletal Symptoms in Patients With Breast Cancer
April 8, 2024 updated by: University of Michigan Rogel Cancer Center
This is a randomized, double-blinded trial of self-acupressure to examine the effect of treatment on aromatase inhibitor (AI)-associated musculoskeletal symptoms (AIMSS) in postmenopausal women with breast cancer.
Acupressure is similar to acupuncture, but uses pressure rather than needles to stimulate specific points on the body.
Acupressure involves applying mild to moderate physical pressure using your fingers, or an assistive device, to these points to try to bring about a physiological change in your body, in this case relief from joint pain and stiffness.
The investigators will also examine effects of acupressure on other symptoms that commonly develop in AI-treated patients.
In addition, changes in stool microbiome with acupressure treatment will be examined in an exploratory way to obtain preliminary information about the effect of acupressure on the gut microbiome in this condition.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
50
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Cancer AnswerLine
- Phone Number: 1-800-865-1125
- Email: CancerAnswerLine@med.umich.edu
Study Locations
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109
- Recruiting
- University of Michigan Comprehensive Cancer Center
-
Principal Investigator:
- Norah L Henry, MD, PhD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Female or male subject aged ≥ 18 years
- Taking the currently prescribed aromatase inhibitor therapy (anastrozole, exemestane, or letrozole) for adjuvant or palliative treatment of breast cancer or for chemoprevention for at least 3 weeks and no more than 2 years at the time of enrollment.
- Planning to take the same AI therapy for at least 12 weeks.
- New or worsening joint pain and/or myalgias since starting the AI therapy, with worst pain score of at least 4 out of 10 on the BPI over the 7 days prior to enrollment.
- Completion of surgery (mastectomy or lumpectomy/partial mastectomy) for treatment of breast cancer at least 3 months prior to enrollment
- Completion of radiation therapy, if given, for treatment of breast cancer.
- Completion of chemotherapy, if given. Concurrent use of LHRHa therapy, anti-HER2 therapy, bisphosphonate therapy, PARP inhibitor therapy, and CDK4/6 inhibitor therapy is permitted.
- Patients receiving treatment with NSAIDs, acetaminophen, opioids, duloxetine, cannabinoids, gabapentin, and/or pregabalin must have been taking a stable dose for at least 30 days prior to enrollment if they plan to continue the drug during study participation. If they do not plan to take the medication during study participation, they should stop the medication at least 7 days before initiation of study treatment.
- Able to self-complete questionnaires in English.
- Able to access WiFi/internet and willing to use an email account or download and use the MyDataHelps app.
- Able to provide informed consent and willing to sign an approved consent form that conforms to federal and institutional guidelines.
Exclusion Criteria:
- Use of acupuncture or acupressure in the past year, or planned use of acupuncture during study participation.
- Use of systemic or transdermal estrogen during study participation.
- Planned surgery during the 12-week study period.
- Concurrent medical or arthritis disease such as painful bone metastases or active rheumatoid arthritis or inflammatory arthritis that could confound or interfere with evaluation of pain or efficacy. Patients with osteoarthritis and asymptomatic bone metastases are eligible.
- Patients with a prior or concurrent malignancy whose natural history or treatment, in the opinion of the treating investigator, has the potential to interfere with the safety or efficacy assessment of the investigational regimen.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Acupressure Arm 1
There are 5 acupoints with 4 of the acupoints performed on both the left and right sides of the body.
Each of the 9 acupoints will be stimulated for 3 minutes per point with the AcuWand giving a total treatment time of 27 minutes daily.
The relaxation acupoints are unlisted in order to maintain blinding.
|
9 acupoints will be stimulated for 3 minutes per point
9 areas will be stimulated for 3 minutes per point
|
Other: Acupressure Arm 2
There are 5 acupoints with 4 of the acupoints performed on both the left and right sides of the body.
Each of the 9 acupoints will be stimulated for 3 minutes per point giving a total treatment time of 27 minutes daily.
The acupoints are unlisted in order to maintain blinding.
|
9 acupoints will be stimulated for 3 minutes per point
9 areas will be stimulated for 3 minutes per point
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in joint pain
Time Frame: baseline and 12 weeks after intervention is started
|
Range 0-10 after 12 weeks of intervention.
Brief Pain Inventory (BPI) questionnaire will be used for this assessment.
Comparison of baseline and 12 week assessment.
|
baseline and 12 weeks after intervention is started
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of patients with at least a 2 point reduction in pain (worst)
Time Frame: baseline and 12 weeks after intervention is started
|
The proportion of patients who have at least a 2-point reduction in worst pain from baseline to 12 weeks will be reported with the corresponding exact binomial confidence intervals in each treatment group.
The proportions will be compared using a chi-square test for each outcome.
Differences from baseline at each time point for worst pain will be summarized via mean and standard deviation.
Linear models using generalized estimating equations will assess the change in worst pain over time between groups similar to the primary endpoint.
Brief Pain Inventory (BPI) questionnaire will be used for this assessment.
|
baseline and 12 weeks after intervention is started
|
Proportion of patients with at least a 2 point reduction in pain (average)
Time Frame: baseline and 12 weeks after intervention is started
|
The proportion of patients who have at least a 2-point reduction in average pain from baseline to 12 weeks will be reported with the corresponding exact binomial confidence intervals in each treatment group.
The proportions will be compared using a chi-square test for each outcome.
Differences from baseline at each time point for worst pain will be summarized via mean and standard deviation.
Linear models using generalized estimating equations will assess the change in average pain over time between groups similar to the primary endpoint.
Brief Pain Inventory (BPI) questionnaire will be used for this assessment.
|
baseline and 12 weeks after intervention is started
|
Difference from baseline for pain interference
Time Frame: baseline, 6 weeks and 12 weeks after intervention is started
|
Brief Pain Inventory (BPI) questionnaire will be used for this assessment.
Differences from baseline at each time point for pain interference (range 0-10) will be summarized via mean and standard deviation.
Linear models using generalized estimating equations will assess the change in pain interference over time between groups similar to the primary endpoint.
|
baseline, 6 weeks and 12 weeks after intervention is started
|
Change in reported sleep disturbance
Time Frame: baseline, 6 weeks and 12 weeks after intervention is started
|
PROMIS Profile 29- sleep disturbance [range 32-73.3].
Patient reported outcomes will be analyzed using linear models and generalized estimating equations with robust variance similar to the primary outcome.
|
baseline, 6 weeks and 12 weeks after intervention is started
|
Change in reported fatigue
Time Frame: baseline, 6 weeks and 12 weeks after intervention is started
|
PROMIS Profile 29-fatigue [range 33.7-75.8].
Patient reported outcomes will be analyzed using linear models and generalized estimating equations with robust variance similar to the primary outcome.
|
baseline, 6 weeks and 12 weeks after intervention is started
|
Change in reported physical function
Time Frame: baseline, 6 weeks and 12 weeks after intervention is started
|
PROMIS Profile 29 -physical function [range 22.5-57].
Patient reported outcomes will be analyzed using linear models and generalized estimating equations with robust variance similar to the primary outcome.
|
baseline, 6 weeks and 12 weeks after intervention is started
|
Change in anxiety
Time Frame: baseline, 6 weeks and 12 weeks after intervention is started
|
PROMIS Profile 29-anxiety [range 40.3-81.6].Patient reported outcomes will be analyzed using linear models and generalized estimating equations with robust variance similar to the primary outcome.
|
baseline, 6 weeks and 12 weeks after intervention is started
|
Change in depression
Time Frame: baseline, 6 weeks and 12 weeks after intervention is started
|
PROMIS Profile 29-depression [range 41-79.4].
Patient reported outcomes will be analyzed using linear models and generalized estimating equations with robust variance similar to the primary outcome.
|
baseline, 6 weeks and 12 weeks after intervention is started
|
Change in cognitive function
Time Frame: baseline, 6 weeks and 12 weeks after intervention is started
|
PROMIS Profile 29-cognitive function [range 29.4-61.2].
Patient reported outcomes will be analyzed using linear models and generalized estimating equations with robust variance similar to the primary outcome.
|
baseline, 6 weeks and 12 weeks after intervention is started
|
Adherence to trial intervention (number of days completed)
Time Frame: 12 weeks after intervention is started
|
Adherence will be calculated based on number of days acupressure is performed The proportion of participants who are fully adherent will be compared between groups using a chi-square test.
|
12 weeks after intervention is started
|
Adherence to trial intervention (number of minutes completed)
Time Frame: 12 weeks after intervention is started
|
Adherence will be calculated based on number of minutes of acupressure performed each day.
The proportion of participants who are fully adherent will be compared between groups using a chi-square test.
|
12 weeks after intervention is started
|
safety of the intervention through reported adverse events
Time Frame: 12 weeks after intervention is started
|
collected using CTCAE version 5.0
|
12 weeks after intervention is started
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Norah Henry, University of Michigan Rogel Cancer Center
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 6, 2024
Primary Completion (Estimated)
May 1, 2026
Study Completion (Estimated)
May 1, 2026
Study Registration Dates
First Submitted
January 16, 2024
First Submitted That Met QC Criteria
January 25, 2024
First Posted (Actual)
January 29, 2024
Study Record Updates
Last Update Posted (Actual)
April 9, 2024
Last Update Submitted That Met QC Criteria
April 8, 2024
Last Verified
April 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- UMCC 2023.084
- HUM00241228 (Other Identifier: University of Michigan)
- BCRF-23-206 (Other Grant/Funding Number: Breast Cancer Research Foundation)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
participant demographics and patient-reported outcomes data will be available to researchers upon reasonable request
IPD Sharing Time Frame
researchers can request data once the primary analysis has been published
IPD Sharing Access Criteria
deidentified data will be available to researchers upon reasonable request
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonTerminatedBreast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Stage IIB | Breast Cancer Stage IIA | Breast Cancer Stage IIIA | Breast Cancer Stage IIIB | Breast Cancer Stage IIIcUnited States
-
CelgeneCompletedBreast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast...United States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Susan G. Komen Breast Cancer FoundationCompletedStage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)WithdrawnStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer
Clinical Trials on Acupressure
-
Mersin UniversityRecruiting
-
Mersin UniversityCompleted
-
Cairo UniversityCompleted
-
University of MichiganNational Cancer Institute (NCI)CompletedBreast Cancer | Sleepiness | Chronic FatigueUnited States
-
University of MichiganCompleted
-
China Medical University HospitalNot yet recruiting
-
Guangdong Provincial Hospital of Traditional Chinese...Completed
-
Chang-Hua HospitalChina Medical University HospitalUnknownInsomnia | Anxiety | Menopause | Auricular AcupressureTaiwan
-
The Hong Kong Polytechnic UniversityUnknownDepression | Insomnia | AnxietyVietnam